Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07356700

Deciphering the Factors of Longevity Through a Multi-Omics Study in Long-Lived Individuals in Hong Kong

Population aging is changing societal dynamics and poses significant global challenges. By 2050, an estimated 1.6 billion people worldwide will be over age 65. Because aging is the primary risk factor for many common chronic diseases, it is essential to reduce the burden of age-related illnesses and promote healthy aging. Hong Kong has one of the largest proportions of elderly adults and has the highest life expectancy in the world, with approximately 11,575 centenarians reported in 2021. Thus, the long-lived population in Hong Kong is a valuable resource for studying healthy aging.

Longevity is a complex trait influenced by genetic, environmental, and behavioral factors. To unveil the mechanisms leading to longevity and healthy aging, researchers focused on centenarians who are extremely long living. Comparisons between long-lived individuals (LLIs) and others have identified several genetic factors and protein markers associated with longevity. Previous centenarian studies revealed that centenarians and their offsprings have a 5-fold lower risk of developing age-related diseases such as Alzheimer's disease and higher cognitive reserve. Certain protein signatures predict longer survival and centenarians acquire aging signatures much later than elderly in the general population. Certain healthy lifestyle leads to higher chance becoming centenarians, including never smoking, exercise and greater dietary diversity.

Despite emerging studies on centenarian population, an integrated approach to understand diverse molecular signatures of longevity is still lacking. Moreover, most of the centenarian studies are based on European descents. To conclude, a multi-omics study examining the genetic, proteomic, metabolomic, and microbiota profiles of LLIs in Chinese population is necessary.

Hence, the study proposed herein aims to identify multi-omics biomarkers that can be used to monitor aging processes and related diseases. In addition, it will provide candidate modifiable factors to promote healthy aging, focusing on Chinese population and local Hong Kong population for the first time. Ultimately, the insights gained from this research will inform the development of effective strategies to enhance healthy aging and improve the quality of life of our local aging population.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Age range

65 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

About this study

The proposed research is a cross-sectional study that will last for 5 years. 500 individuals aged 95 years or older (i.e., LLIs) from various communities in Hong Kong will be recruited. LLIs will be recruited through advertisements as well as collaboration with geriatric community centers and non-government organizations (NGOs). Participants will be recruited at geriatric centers and NGOs to collect demographic information, family history, medical history, and medication records. Blood samples for clinical chemistry and multi-omics study will be collected. Furthermore, cognitive and functional assessment using various scoring systems will be performed to assess cognition and activities of daily living.

In addition, a control cohort of elderly people (aged 65-94 years, n = 2,000) based on our in-house Alzheimer's disease registry and community cohort will be developed. Accordingly, demographics, clinical profiles, cognitive and functional scores, and multi-omics data between the LLI and control cohorts will be compared.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Han Chinese ethnicity
  • Able to provide official evidence for being 95 years or older (e.g., a birth certificate)
  • Mentally capable of consenting to join the study with or without informant presence
  • Consent to donation of biospecimens (i.e., blood)

Exclusion criteria

  • Mentally incapable of consenting to join the study even with the presence of an informant
  • Refusal to provide blood samples

Treatment and study plan

Observational

Other

Clinical profile, blood collection, cognitive assessment, questionnaires on modifiable risk factors

Primary outcomes

  1. Biobank of LLIs

    Time frame: 3-5 years

    A comprehensive cohort of LLIs with data on demographics, clinical profiles, cognitive and functional assessments, lifestyle, and genomic and proteomic biomarkers

  2. Genetic and modifiable factors associated with longevity

    Time frame: 3-5 years

    Genetic and modifiable factors associated with longevity

Secondary outcomes

  1. AI-based model

    Time frame: 5 years

    AI-based model to elucidate candidate modifiable factors that promote healthy aging

  2. Healthy aging strategies

    Time frame: 5 years

    Recommendations for personalized strategies to enhance healthy aging in the elderly population

Study contacts

Contact information is provided by the study sponsor or research team.

Hiu Yi Wong, PhD

CONTACT

[email protected]

+852-23587344

Nancy Ip, PhD

CONTACT

[email protected]

+852-23587304

Sponsors and collaborators

Lead sponsor

Hong Kong University of Science and Technology

Other

Collaborators

  • Hong Kong Center for Neurodegenerative Diseases

Registry information

Important dates

Study start
2026
Primary completion
2031
Study completion
2031
First posted
Jan 21, 2026
Registry last updated
Jul 8, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.